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Agents which can either trigger proliferation of β-cells or induce neogenesis of β-cells from precursors would be of pivotal role
in reversing diabetic manifestations. We examined the role of ﬂavonoid rich fraction (FRF) of Oreocnide integrifolia leaves using
a mice model of experimental regeneration. BALB/c mice were subjected to ∼70% pancreatectomy (Px) and supplemented with
FRF for 7, 14, and 21 days after pancreatectomy. Px animals displayed increased blood glucose levels and decreased insulin titres
which were ameliorated by FRF supplementation. FRF-treated mice demonstrated prominent newly formed islets budding oﬀ
from ducts and depicting increased BrdU incorporation. Additionally, transcripts levels of Ins1/2, Reg-3α/γ,N g n - 3 ,a n dP d x - 1
were upregulated during the initial 1 week. The present study provides evidence of a nutraceutical contributing to islet neogenesis
f r o md u c t a lc e l l sa st h em o d eo fβ-cell regeneration and a potential therapeutic for clinical trials in management of diabetic
manifestations.
1.Introduction
Pancreatic acinar and islet components diﬀerentiate by an
epithelial-mesenchymal interaction involving a foregut en-
dodermal evagination and the splanchnic mesoderm [1].
During this process, multipotent stem cells diﬀerentiate into
exocrine and endocrine phenotypes [2]. Islet endocrine cells
are purported to develop from embryonic duct-like cells by a
process of budding resulting in islet morphogenesis in the
duct-associated mesenchyme [3], and subsequent orches-
trated sequence of gene action lays down the various classes
ofendocrinecellsintheislet.Postnatalandadultβ-cellsseem
to have poor replicative capacity as they are of a terminally
diﬀerentiated state, with only about 3% of cells exhibiting
potential for proliferation [4].
Decreased β-cell number or functioning is characteristic
of diabetes mellitus, whereas an actional reduction in β-cell
number by chemical insult or infection is the cause of hypo-
insulinemia and type 1 diabetes. Diet or obesity-induced
type 2 diabetes results in initial islet compensation with the
consequent eﬀect of decreased β-cell functioning and de-
struction due to islet decompensation. It is clear by now
that a reduction in β-cell number to a critically low level is
correlatable with progression and outcome of diabetes [5–
7]. Roughly about 80% of islet cell population is represented
by β-cells, and the ﬁnal β-cell mass is established during
prenatal life through sequential steps of commitment to
pancreatic, endocrine, and then β-cell progenitors followed
by diﬀerentiation and proliferation of speciﬁed cells [8].
Though β-cell insuﬃciency associated with diabetes in2 Evidence-Based Complementary and Alternative Medicine
general was rectiﬁed by islet transplantation [9], alternative
approaches involved stimulation of regeneration of endoge-
nous pancreatic β-cells. Three diﬀerent processes targeted to
meet this alternative approach include (1) proliferation
of preexisting β-cells, (2) neogenesis from intrapancreatic
progenitor stem cells, and (3) transdiﬀerentiation from pan-
creatic acinar cells. Experimental induction of β-cell regen-
eration or neogenesis in diabetic individuals ﬁnds basis from
thefactthat,pancreashasthepotentialtorespondtochanges
in islet cell mass and regenerate β-cells by a probable intra-
pancreatic “sensing” mechanism [10, 11]. There is suﬃcient
evidence for presence of islet stem cells or progenitors in
adult pancreas located within or near pancreatic ducts that
can under appropriate stimuli diﬀerentiate into endocrine
cells [12–14]. Even other workers have provided evidence for
presence of islet progenitor cells and the possible ability of
these cells to form mature functional islets in streptozotocin
diabetic mice [12, 15].
Since insulin deﬁciency is the prime basis of all diabetic
manifestations, strategies that can trigger β-cell regenera-
tion/neogenesis would be of pivotal signiﬁcance in therapy
and cure of diabetes. In this behest, agents which can either
trigger proliferation of β-cells or induction of neogenesis
of β-cells from precursors would be of great merit in re-
versing diabetic complications. Reports have appeared in
recent times regarding inductive agents that have been
shown to stimulate regeneration and replenishment of islet
cells. Fern´ andez-Alvarez et al. [16] have in this context
demonstrated stimulated regeneration within pancreas of
streptozotocin-treated neonatal mice by tungstate.
Plants have always been an exemplary source of drugs,
and many of the currently available drugs have been derived
directly or indirectly from them. A wide array of plant-
derived active principles representing numerous chemical
compounds has demonstrated activity consistent with their
possible use in the treatment of NIDDM [17–21].
Our studies with Oreocnide integrifolia (OI) extract, in
terms of hyperglycemia metabolic alterations, and dyslipi-
demia, in type 1 and type 2 diabetes models of animals,
have been encouraging [22]. Hence, it was thought pertinent
to evaluate the probable islet regenerative potential of ﬂa-
vonoid rich fraction (FRF) of Oreocnide integrifolia in pan-
createctomized animal model. To this end, BALB/c mice
have been subjected to subtotal pancreatectomy (70%) and
the regenerative ability tested by administering FRF to pan-
createctomized mice.
2.MaterialsandMethods
2.1. Plant Material. Fresh green leaves were collected during
the month of October from Imphal district (Manipur) and
authenticated by botanist Dr. Hemchand Singh, D.M. Col-
lege of Science, Manipur University. A voucher specimen
(#344) of the herbarium has been deposited at the same
department for future reference.
2.2. Flavonoid Rich Fraction. Brieﬂy, one hundred g of air-
dried leaves were ground to ﬁne powder and soaked in
70% ethanol for 24h with continuous stirring. The soaked
mixture was ﬁltered using Whatmann Number 1 ﬁlter paper
and the pellet discarded after centrifugation of the ﬁltrate
at 10,000rpm at room temperature (25◦C). The supernatant
was concentrated in vacuo by means of a rotavapor and then
dissolved in as little water as possible and washed three times
with chloroform. The resultant residual layer after extraction
three times with ethyl acetate and subjected to concentration
in vacuo served as the ﬂavonoid rich fraction (FRF).
2.3. HPLC Fingerprint of Flavonoidal Fraction. Chromatog-
raphy was performed on Shimadzu (Shimadzu Corpo-
ration, Kyoto, Japan) chromatographic system equipped
with Shimadzu LC-20AT pump and Shimadzu SPD-20AV
absorbance detector. Samples were injected through a Rheo-
dyne 7725 injector valve with ﬁxed loop at 20μL. Data acqui-
sition and integration was performed using Spinchrome
software (Spinco Biotech, Vadodara). HPLC grade acetoni-
trile (ACN) and methanol (Spectrochem Ltd, Mumbai),
analytical grade ammonium acetate (Merck, India), puriﬁed
water from Millipore Milli-Q system were used for the
experiment. For qualitative analysis, about 20mg sample
(ﬂavonoid rich fraction) along with standards (ﬂavonoids)
were dissolved in methanol and ﬁltered through a 0.22μm
Millipore membrane ﬁlter. HPLC separation of ﬂavonoidal
rich fraction was performed at room temperature on a
reversephaseC18(250mm ×4.6mmi.d.,5μmpartic lesiz e)
columnwithmobilephasecomposedof0.5%v/vphosphoric
acid:methanol(50:50).Theﬂowratewassetto1.0mL/min,
and UV detection was carried out at 254nm. The injection
volume was 20μL (Figure 1(a)).
3. HPTLC Fingerprint of Flavonoidal Fraction
A Camag HPTLC system equipped with an automatic TLC
sampler (ATS 4), TLC scanner 3 integrated with software
(WinCATS version 1.4.2), and UV cabinet and automatic
developing chamber ADC2 with humidity control facility
was used for the analysis. The samples were applied using
automated TLC sampler in 10mm bands, 10mm from the
bottom,and15mmfromthesides,with8mmspacebetween
the two bands. Plates were developed in software-controlled
Camag automatic developing chamber ADC2 presaturated
with 10mL of developing solvent phase for 30min at room
temperature (25◦C), and relative humidity was maintained
(45%). The plates were developed in ethyl acetate:formic
acid:glacial acetic acid:water; 100:11:11:26 (v/v). NP -
PEG reagent was used to derivatize ﬂavonoids (Figure 1(b))
3.1. Animals and Operative Procedures. Adult female mice
of BALB/c strain around 7-8 weeks old (25–27gm)
were obtained from Cadila Pharmaceuticals, Ahmedabad,
Gujarat, and acclimatized in the department of animal house
for one week. The experiment was carried out according to
the guidelines of the Committee for the Purpose of Control
and Supervision of Experiments on Animals, India, and
approved by the Animal Ethical Committee of DepartmentEvidence-Based Complementary and Alternative Medicine 3
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Figure1:Represents(a)HPLCﬁngerprintofﬂavonoidrichfractionwithmarkercompounds,(b)HPTLCﬁngerprintofFlavonoidalfraction
derivatized with NP-PEG reagent, (c) schematic representation of experimental paradigm, (d and e) plasma blood glucose levels and insulin
titers of Px and Px + FRF groups. All values are expressed as mean + SEM of six animals (one-way ANOVA) where, •P<0.05,  P<0.01,
 P<0.001: sham was compared to other experimental groups; δP<0.001: Px day 7 was compared Px day 7 + FRF; white numbered 3 circle
P<0.001: Px day 14 was compared to Px day 14 + FRF; black numbered 3 circle P<0.001: Px day 21 was compared to Px day 21 + FRF.
of Zoology, The M.S. University of Baroda, Vadodara
(Approval Number 827/ac/04/CPCSEA).
Partial pancreatectomy (Px) was performed according
to the procedures of Bonner Weir et al. [23] and Hardikar
et al. [24]. Brieﬂy, mice were anesthetized using ketamine
(150mg/kg) and xylazine (10mg/kg) intraperitoneally. A
midline abdominal incision allowed exteriorization of the
splenic lobe of the pancreas (between the gastroduodenal
junction and the spleen). Approximately ∼70% percent
pancreatectomy was performed by gently denuding the
pancreatic tissue from the splenic lobe using cotton-tipped
swabs soaked in 0.9% saline, leaving the mesentric pancreas4 Evidence-Based Complementary and Alternative Medicine
intact. Incisions were closed using 5–0 catgut absorbable
sutures (Ethicon), and 3M Vetbond tissue adhesive. The
skin was clipped using 9.0mm skin staples (Leuckoclip
SD, Australia), and topical ointment (Soframycin, Aventis
Pharma. Ltd., Pune, India) was applied over the sutured
wounds following surgery. Sham-operated animals were
anesthetized, and the pancreas was gently held through the
midline incision with cotton applicators for 60 seconds.
The skin was sutured as in the case of pancreatectomized
animals. All animals (pancreatectomized and sham oper-
ated) received an intraperitoneal injection of gentamycin
(3mg/kg body weight), ampicillin (20mg/kg body weight)
and were administered analgesics (buprenorphine HCl in
normal saline 0.1mg/kg subcutaneously).
3.2. Experimental Groups. The animals were divided into
7 groups, consisting of at least 6 animals, each and were
sacriﬁced at predeﬁned time points. Group 1: Sham oper-
ated; Group 2: Day Px 7; Group 3: Day Px 14; Group
4: Day Px 21; Group 5: Day Px 7 + FRF; Group 6: Day
Px 14 + FRF; Group 7: Day Px 21 + FRF. FRF groups
received 250mg/kg body weight of ﬂavonoidal rich fraction
intraperitoneally starting from the day of surgery, while
sham operated and pancreatectomized groups received 0.5%
sodium carboxymethylcellulose as vehicle (Figure 1(c)).
Animals were fasted overnight prior sacriﬁce. The exper-
iment was carried out according to the guidelines of the
Committee for the Purpose of Control and Supervision of
Experiments on Animals (CPCSEA), India, and approved by
the Animal Ethical Committee of Department of Zoology,
The M.S. University of Baroda, Vadodara (Approval no.
827/ac/04/CPCSEA).
3.3. Glucose and Insulin Measurements. Plasma glucose was
measured by the tail-snipping method using one-touch-
glucometer (Elegance, USA). Plasma insulin was quantiﬁed
according to manufacturer’s protocol using mouse insulin
ELISA kit (Mercodia Diagnostics, Uppsala, Sweden).
3.4. In Vivo BrdU Pulse Labelling. In-vivo pulse-labelling
with 5-bromo-2-deoxyuridine, a thymidine analogue, and
subsequent immunostaining of the incorporated BrdU were
carried to mark the cells that synthesized DNA during the
incubation time. Six hours before sacriﬁce, BrdU labelling
reagent (100mg/kg body weight, Sigma Aldrich, MO) was
injected intraperitoneally into Sham, Px and Px + FRF
groups of animals to label proliferating cells. BrdU stock
was prepared in phosphate buﬀered saline (PBS), (pH 7.2,
0.1M) with 0.1NNaOH at 20mg/mL. After sacriﬁce, a
portion of the pancreas from the same anatomical location,
including the main pancreatic duct, was immediately ﬁxed
in 4% paraformaldehyde buﬀered with 0.01mol/L sodium
phosphate, pH 7.4 (PBS) overnight at 4◦C, dehydrated with
ethanol and embedded in paraﬃnw a x .
3.5. Haemtoxylin and Eosin Staining. Pancreatic tissue sec-
tions were incubated at 60◦C for 10min, deparaﬃnised in
xylene, and then stained with Harris haematoxylin (Sigma-
Aldrich,StLouis,USA).Sectionswerethendehydratedusing
gradients of ethanol and ﬁnally in 100% ethanol before
staining with Eosin Y (Hi-Media Labs, Mumbai, India).
Slides were then rehydrated by downgrading them in ethanol
and mounted in DPX. Images were captured using Leica
DMRB binocular microscope with digital camera.
3.6. Immunohistochemistry and Confocal Microscopy. Five
microns thick serial sections were mounted on Poly-L-
lysine (Sigma Aldrich, MO, USA). For immunohistochem-
ical detection of BrdU-incorporating nuclei, DNA was ﬁrst
denatured to expose the antigen by incubating the tissue
sections in 1NHCl for 45min at 45◦C. The sections were
rinsed three times for 5min each in PBS then incubated
with primary antibodies to mouse monoclonal BrdU (1:200
Sigma Aldrich, MO, USA), Guinea pig anti insulin (1:200;
Invitrogen, USA), Rabbit CK-19 (1:200, Abcam, USA),
rabbit Pdx-1 polyclonal (1:400, Millipore) in 0.1% Triton-
X solution in antibody diluent solution, for 12h at 4◦C. For
Pdx-1, antigen unmasking step was performed in microwave
using sodium citrate buﬀer. Nonspeciﬁc blocking was per-
formed using 4% normal donkey serum and 1% BSA. Next,
the labelled sections were washed with PBS (3 times at 5min
each), and secondary incubation was carried out in the dark
for 2hr at room temperature. For the secondary incubation,
appropriate ﬂuorochrome-conjugated secondary antibody
Alexa-Fluor 488 and Alexa-Fluor 546F(ab
 )2 secondary
antibodies (Molecular Probes, OR, USA) were used at
1:200 dilution. DAPI was used to visualize nuclei. Negative
controls were run where the primary antibody incubations
were omitted. After 2hr, the tissue sections were washed
in calcium magnesium containing PBS and mounted with
antifade mounting medium Vectasheild (Vector Laborato-
ries,Burlingame,CA).Alaserscanningconfocalmicroscope,
model LSM 510 META (Carl Zeiss, Germany), was used
with a 63X1.4NA pan Apochromat objective with optical Z
sections was taken at ∼0.8 microns. Magniﬁcation, laser and
detectorgains,andpinholesettingsweresetbelowsaturation
and were identical across samples.
3.7. Morphometry and Image Analysis. For proliferation
index of BrdU-labelled cells, number of BrdU+ cells per
islet was counted in the insulin positive or glucagon positive
area. At least 10 islets per animal from nonoverlapping
areas were counted, and islets of less than 100 microns
were considered as small, islets while those that were more
than 100 micrometer in size were considered as large islets.
Acinarcellproliferationanalysiswasperformedbyrandomly
acquiring ﬁve DAPI/BrdU areas of acinar cells from each
section. Acinar cells were counted for total BrdU+ and total
DAPI+ nucleiinday7.Individualanimalresultsofpancreatic
acinar tissue each represent 10 ﬁelds counted per animal
BrdUincorporationinductswasalsocountedinday7.Ducts
less than 100 microns (internal diameter) were considered
small-duct while those of 100–300 microns were considered
large ducts. Number of ducts giving rise to islets was countedEvidence-Based Complementary and Alternative Medicine 5
using H&E staining and classiﬁed as large and small ducts
based on internal diameter.
3.8. Quantitative Real-Time PCR. Pancreas was homoge-
nized in Trizol (Invitrogen, Carlsbad, CA), and RNA was
isolated as per the manufacturers’ instructions, measured
on ND-1000 spectrophotometer (NanoDrop Technologies,
Wilmington, DE) and taken for reverse transcription and
TaqMan-based probe quantitative real-time PCR. First
strand cDNA synthesis was carried out using “high capacity
cDNA archive kit” (Applied Biosystems, Foster City, CA).
PCR was performed in 10μL total volume in 96-well plates
using cDNA prepared from 100ng of total RNA on a 7500
FAST real-time PCR cycler (Applied Biosystems, Foster City,
CA). Primers and probes were Assay-on-Demand (Applied
Biosystems, Foster City, CA). All qRT-PCR results are nor-
malized to 18S (VIC-labelled) ribosomal RNA carried out in
duplex reaction (with FAM-labelled target gene probes) to
correct for any diﬀerences in RNA input. All PCR reactions
were analyzed after 35 cycles of reaction. The ΔΔ Ct method
of relative quantiﬁcation was used to determine the fold
change in expression. This was achieved by ﬁrst normalizing
the resulting threshold cycle (Ct) values of the target mRNAs
to the Ct values of 18S internal control of the same sample
(ΔCt = Cttarget − Ct18S). It was further normalized with the
experimental control (ΔΔCt = ΔCttarget − ΔCtcontrol). The
fold change in expression was then obtained (2−ΔΔCt).
4. Results
4.1. Plasma Glucose and Insulin Levels. Pancreatectomized
mice entered into a phase of signiﬁcant hyperglycaemia
within one week, which persisted even at three weeks. Pan-
createctomized mice treated with FRF extract showed sig-
niﬁcantly lower hyperglycaemia, which showed a slow but
gradual decline through one to three weeks (Figure 1(d)).
Plasma insulin level which was signiﬁcantly low one week
after pancreatectomy showed a gradual increase through
weeks two and three. Though there was no signiﬁcant
diﬀerence in plasma insulin titre of Px FRF mice at week one
and two compared to Px, during the third week, the insulin
level showed noticeable increase compared to Px animals
(Figure 1(e)).
4.2. Histological Observations. Evaluation of routine HE-
stained sections of pancreas revealed intact islet histoarchi-
tecture along with acinar cells (Figure 2(a)), while bunch of
endocrine cells budding oﬀ from small pancreatic ductules
were observed by day 7 of Px. Duct-associated vascular
channels are also visible in the neighbourhood of budding
endocrine cells. By day 14 (Figures 2(b) and 2(c)), the bud-
ded oﬀ chumps of endocrine cells appear as well organized
larger islets. By day 21, the newly formed islets have acquired
normal looking demarcated islets that seemed to be sinking
into the nearby acini. FRF-treated pancreatic remnants seem
to show more prominent islet-like buds getting organized
around pancreatic ducts by day 7 (Figures 2(d), 2(e), and
2(f)) with increased cell density, probably by way of prolif-
eration of ductal precursor cells. Relatively more number of
buds seems to be originating in FRF-treated pancreas. Clear
association with vascular channels is also visible. By 14 day
after Px (Figures 2(g), and 2(h)), FRF-treated mice seem to
display prominent and relatively greater acinar organizations
with prominent ductal epithelia. By day 21 (Figure 2(i)),
well-organizedisletsbetweenaciniinthevicinityofductsare
visible. The FRF-treated pancreas demonstrated increased
isletneogenesis.Overallquantitationofductsassociatedwith
islets showed 37.22% in Px + FRF mice compared to 12.87%
in Px group of animals by day 7 after Px (Figure 2(o)).
4.3. BrdU Incorporation in Islets, Ducts, and Acinar Cells.
There was a signiﬁcant increase in BrdU incorporation by
day 7 to day 21 in Px + FRF-treated mice (Figures 3(d),
3(e), and 3(f)) compared to Px group (Figures 3(a), 3(b),
and 3(c)) especially in islets clusters <100μmi ns i z e .A n
overall quantitative evaluation of BrdU labelling in terms of
percentageincorporation revealeda temporal increase across
all sizes of islets (Figure 3(g)) with a signiﬁcantly greater
incorporation in Px + FRF pancreas.
Insulin immunoreactivity along with BrdU incorpora-
tion in ducts (Figure 4(a)) by day 7 after Px showed clearly
increased BrdU labelling. A quantitative estimate of BrdU
label in the ducts revealed signiﬁcantly higher labelling in
Px + FRF than in Px pancreas (Figures 4(a) and 4(b)). In
comparison, smaller ducts seemed to show relatively higher
labelling than the larger ducts (Figure 4(c)). Moreover, Px +
FRF-treated mice demonstrated CK-19/insulin coexpression
within ducts (Figure 4(d)).
In terms of BrdU incorporation, glucagon positive cells
showed equal degree of proliferation in both Px and Px +
FRF pancreas (Figures 4(g) and 4(h)). Almost same was the
case even for acinar cells, though an insigniﬁcantly higher
incorporation was the feature in Px + FRF pancreas (Figures
4(e) and 4(f)).
4.4. Immunolabelling of Insulin/Pdx-1, C-Peptide. Both Px
and Px + FRF showed increment in insulin and Pdx-1
immunoreactivity seven days after Px (Figures 2(j) and
2(k)). However, Px + FRF group showed 33.1% islet cells
coexpressingPdx-1/insulincomparedto23.3%inPxanimals
after 7 days after Px. (Figure 2(l)). Further, C-peptide
immunostaining was carried to visualize functional islets
(Figures 2(m) and 2(n)).
4.5. Proinsulin 1 and 2 Transcripts. Both the proinsulin
transcripts showed a signiﬁcant decrement seven days after
Px with a relatively lesser decrement in Px + FRF pancreas
(Figures5(a)and5(b)).Expressionswereincreasedgradually
over 14 and 21 days after Px with signiﬁcantly high expres-
sion in FRF treated pancreas.
4.6. Reg-3α and Reg-3γ Transcripts. Both Reg-3α and Reg-3γ
transcripts were upregulated maximally at day 7 after
Px with FRF-treated mice pancreas showing signiﬁcantly
high expression. Both the transcripts decreased gradually to6 Evidence-Based Complementary and Alternative Medicine
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reach lowest levels by day 21 after Px with the levels in Px
+ FRF being relatively higher at all times (Figures 5(c) and
5(d)).
4.7. Pdx-1 and Ngn-3 Transcripts. Upregulated expression of
both transcripts were the feature at day 7 after Px with
relatively greater expression in Px + FRF mice pancreas.
Transcript levels of both genes decreased thereafter through
day 14 to reach the lowest levels at day 21, with the transcript
levels in Px + FRF pancreas being relatively higher at all time
periods (Figures 5(e) and 5(f)).
5. Discussion
The present study on pancreatectomized (70%) BALB/c
mice from day 7 to day 21 provides an evidence for a ductal8 Evidence-Based Complementary and Alternative Medicine
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Figure 4: (a)–(d) Images represent BrdU incorporation in ducts, (e, f) acinar, and (g, h) glucagon cells after day 7Px. White arrows denote
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contribution in islet neogenesis with speciﬁc expression of
regeneration and proliferation promoting genes. Literature,
in recent times, is replete with a spectrum of experimental
evidences and contentions supporting diﬀering hypotheses
of islet/β-cell formation under a variety of natural and ex-
perimental conditions. These studies have tended to suggest
widely diﬀering mechanisms like islet/β-cell neogenesis
from ductal precursors/stem cells [25–27] proliferation of
diﬀerentiated islet β-cells or intraislet precursor β-cells [28–
30], acinar and stellate cells [31, 32], or even both acinar and
ductal cells [33]. Removal of 70% pancreatic mass in BALB/c
strain of mouse is clearly marked by a deﬁnitive regenerativeEvidence-Based Complementary and Alternative Medicine 9
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reconstitution of pancreatic mass by signiﬁcant islet neogen-
esis from ductal cells. The histological observations provide
compelling evidence for nodular budding of diﬀerentiating
endocrine cells that get organized as deﬁnitive islets by 21
days after Px. Histological observations further provide
convincing evidence for quantitatively greater number of
neogenic islet nodes and β-cell density in the pancreas of
mice treated with ﬂavonoid rich fraction, suggesting the
additional stimulatory role of OI extract ﬂavonoids over
and above that of the stimulatory trigger provided by the
substantial decrement in pancreatic mass. Augmented rates
o fc e l lp r o l i f e r a t i o ni nd u c t a lp r e c u r s o rc e l l si nP xp a n c r e a s
and even higher proliferation in Px + FRF are clearly
indicative by the recorded higher BrdU incorporation and
BrdU labelling indices. The percentage increase in BrdU
incorporation seen herein provides strong evidence for the
greater potential of FRF to augment ductal precursor/stem
cell proliferation on subtotal pancreatectomy.
The fact that BrdU incorporation is seen even in pre-
sumptive islets associated with ducts also denote continuing
proliferation of committed islet cells (β-cells) even after
budding oﬀ from the ducts. Apparently, islet growth and
increase in cell mass could occur by proliferation of imma-
ture/young β-cells. Such intraislet proliferation of β-cells is
documented even in other conditions of β-cell regeneration.
Comparatively, proliferation within smaller islets is more
intense than in larger islets. Apparently, smaller islets rep-
resent newly budded neogenic endocrine cell clusters from
the ducts, and hence the tempo of proliferation initiated
within the ducts due to triggering of initiation of pancreatic
regeneration still persists. Though there is a slowing down
of the tempo of proliferation within the larger follicles,
proliferativeincrementofβ-cellmassneverthelesscontinues.
Though the BrdU incorporation studies also identify acinar
cell proliferation during pancreatic restoration after surgery,
their contribution to islet morphogenesis is almost nil in
the present set up of pancreatic regeneration induced by
subtotal pancreatectomy. However, there are some evidences
for contribution of acinar cells in islet β-cell formation by
transdiﬀerentiation under conditions of neoplastic conver-
sion through EGFR signaling [32], under in vitro conditions
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It is clear by now that pancreatic dysfunctioning, like in
cases of pancreatectomy, pancreatitis, or pancreatic ductal
obstruction, is characterized by activation of endogenous
stimulators of pancreatic regeneration that may involve
soluble autocrine, paracrine, and juxtacrine modulators [24,
36]. Some of the trophic factor therapies employed for
β-cell/islet regeneration are INT, a combination of gastrin
and epidermal growth factor [37, 38], glucagon-like peptide-
1(GLP-1) [39], and INGAP [40, 41]. What stimulus is
provided by surgical stress of pancreatectomy or, loss of a
critical mass of pancreas is not clear though, it is clear
fromtheobservations thatapowerfulinductive regeneration
signal is generated. Since a powerful environmental milieu
needs to be created for bringing about islet neogenesis
and pancreatic regeneration, generation of a number of
initially exclusive and/or inclusive signals can be considered
as a distinct possibility. It is worth contemplating on the
possibility of Pdx-1 reduction as one of the possible cues for
islet neogenesis in this scenario. Compelling thrust for such a
consideration is provided by the fact that Pdx-1 reduction is
a distinct possibility consequent to more than 70% pancreas
ablation/loss as this transcription regulator is expressed in
mature β-cells for maintenance of β-cell functions and
prevention of glucagon production. Pdx-1 is an important
transcription factor essential initially for early delineation of
pancreas from the posterior foregut endodermal analogue
[42] and later for maturation of endocrine lineages and β-
cell diﬀerentiation [43]. Though ductal precursor cell prolif-
eration is triggered by decrease in Pdx-1 and other inducer
trophic factors, the ultimate eﬀector molecules appear to
be islet neogenesis-associated protein (INGAP) and/or other
related group-three regeneration promoting proteins (Reg
3), which make the proliferating ductal cells to diﬀerentiate,
grow into a mass, and bud oﬀ from the duct to form islet-like
aggregations[35,44].Thoughasuperfamilyofregeneration-
promoting proteins, the Reg superfamily consisting of Reg-1,
Reg-2,Reg-3isoforms,andReg-4andIGNAPareallreported
to ﬁnd expression in pancreas during β-cell regeneration
[32, 44], a careful consideration of these reports reveals the
fact that the expressions of these genes/proteins are related to
the type of pancreatic insult and further that Reg-1, Reg-2,
and Reg-3β expressions are more characteristic of intraislet
β-cell proliferation and regeneration, while Reg-1, Reg-3α,
and Reg-3γ expressions are more under conditions of islet
neogenesis from nonislet sources. In this context, the present
study clearly shows higher expression levels of Reg-3α and
Reg-3γ transcripts after pancreatectomy. Though both the
genes are upregulated, Reg-3γ upregulation seems to be
relatively of a greater degree than Reg-3α and that maximal
expression is recorded on day 7 after Px with gradual decline
through 14 and 21 days after Px. The degree of upregulation
of both the genes is signiﬁcantly greater in Px + FRF mice
than in Px mice. Apparently, the ﬂavonoid rich fraction
exerts an additive eﬀect on transcriptional activation. The
observedgreaterdegreeofductalcellproliferationasassessed
by BrdU incorporation and the greater number of duct
associated nodular buds and the greater number of islets
in Px mice exposed to FRF in comparison to nonexposed
mice agree well with the highly augmented Reg-3α and
Reg-3γ expressions. Islet neogenesis would, however, require
speciﬁcexpressionofendocrineprecursorcommitmentgene
to guide the neogenic precursor cellsto diﬀerentiate into islet
speciﬁc endocrine cells. Studies on embryonic development
of pancreas have identiﬁed neurogenin-3 (Ngn-3), a bHLH
transcription factor, as the gene that commits the Hnf-1β+
transition duct cells to endocrine progenitors [38].
In the present study, Ngn-3 mRNA expression is signif-
icantly upregulated by 8-fold at day 7 after Px, which gets
reduced to 6-fold by day 14 and to a mere 2-fold by day 21.
In contrast, FRF-treated Px mice show nearly 12-fold upreg-
ulation at day 7 after Px, and the upregulated expression
persists at 5-6-fold high even at 14 and 21 days after Px.
This would suggest islet neogenesis after Px in BALB/c mice
exposed to FRF, and this ﬁnd-excellent correlation with the
observed duct-associated islet neogenesis following Px and
the relatively greater number and size of diﬀerentiating islets
inFRF-treatedPxmice.NotonlyisNgn-3expressionnoticed
at the time of endocrine speciﬁcation during pancreatic
morphogenesis [25, 45], but, also during islet neogenesis
during pancreatic regeneration in the adult [46].
The importance of Ngn-3 in the speciﬁcation of pre-
cursor cells for the various endocrine lineages in pancreatic
islets is fully established by the reported inhibition of islet
neogenesis by miRNA-induced Ngn-3 gene silencing [47,
48]. It has also become clear from some recent studies that
models of diabetic animals in which intraislet precursor or
adult β-cell proliferation plays a primary role in β-cell re-
generation, Ngn-3 expression is not important as Ngn-
3 inhibition was of no consequence and normal β-cell
regeneration occurred [29, 47]. It is also of interest to note
that a higher glucose level facilitates pancreatic endocrine
cell development by potentiating the expression of Neuro-
D, a downstream target of Ngn-3 [49]. Presumably, as the
hyperglycemia characteristic of Px as in the present case can
favour islet endocrine cell development by complimenting
the function of Ngn-3. The higher and larger duration
persistence of Ngn-3 expression in FRF-treated mice as well
correlatable with the noticed larger number and size of
neogenic FRF-treated pancreas as substantiated by the doc-
umented greater immunoreactivity for insulin.
ThegreaterinsulinimmunoreactivityintheisletsofFRF-
exposed mouse pancreas again ﬁnds correlation with the
recorded relatively lesser inhibition of Ins-1 and 2 proinsulin
transcripts. The greater degree of inhibition of insulin bio-
genesis seen in Px mice is eﬀectively minimized by FRF
exposure. Apparently, treatment with FRF extract has sig-
niﬁcant favourable inﬂuence on insulin synthesis as seen
by the relatively higher plasma insulin titres in FRF-treated
mice. This increasing proinsulin mRNA expression and
recovering insulin levels may suggest greater number of β-
cells as also evidenced by the greater immunoreactivity for
insulininFRF-exposedmice,whichmaybearsomerelevance
in the context of recently reported new function of Pdx-1
[50]. According to their ﬁnding, the C terminus of Pdx-1
has a novel function of forming a molecular complex with
Hnf6 and inducing the expression of Ngn-3 and it also
indirectly regulates ngn-3 expression by controlling the
regulatory network of Sox-9, Foxa2, Hnf6, and Hnf1b. FromEvidence-Based Complementary and Alternative Medicine 11
this ability of Pdx-1 to upregulate the expression of Ngn-3
and also its known role in proliferating and diﬀerentiated β-
cells, it is easily inferable that the presently observed greater
number of islets and β-cells with the FRF supplementation
is relatable with the greater Pdx-1 expression as substan-
tiated by the immunocytochemical and qPCR results. This
inference ﬁnds further substantiation by the herein recorded
minimalglucagonpositivecellsandsimilarnumberofα-cells
proliferation as detected by BrdU incorporation in both Px
and Px + FRF mice.
Overall, the present ﬁndings indicate islet neogenesis
as the mode of β-cell regeneration in pancreatectomized
BALB/C mice and provide evidence for ﬂavonoidal rich
fraction to have enhancing inﬂuence on islet neogenesis and
greater β-cell regeneration by as yet unknown inﬂuence on
the genetic network controlling islet neogenesis and β-cell
diﬀerentiation. The reports of Ogata et al. [51]a n dK o j i m a
and Umezawa [52] of the ability of caryophylline a Vinca
alkaloid in inducing diﬀerentiation of pancreatic endocrine
precursor cells and of Sidhu et al. [53] of Rosiglitazone to
promote β-cell regeneration from stellate cells are relevant in
the present context. It is also clear from the present ﬁndings
that, ductal cells can serve as progenitors for islet neogenesis
in response to appropriate triggering stimulation(s) gener-
ated by the stress of substantial pancreatic loss, by reverting
toaplasticphenotypestatesimilartoembryonicprogenitors,
as has been suggested by a working hypothesis extended by
Bonner-Weir and Sharma [54]. This also overrules the myth
ofresistancetonuclearreprogrammingoffullydiﬀerentiated
cellsand,assuch,reprogrammingofpancreaticexocrinecells
has been adequately documented [55].
More focused and reshaped experimental approaches
need to be undertaken to fully fathom the cell types involved
in reprogramming and the speciﬁc signals generated under
various types of pancreatic stress and the underlying genome
organization that need to be attend for reprogramming, as
also opined by Bukys and Jensen [56].
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